Hemostemix Inc - Asset Resilience Ratio

Latest as of September 2025: 10.87%

Hemostemix Inc (HEM) has an Asset Resilience Ratio of 10.87% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Hemostemix Inc for a breakdown of total debt and financial obligations.

Liquid Assets

CA$145.58K

≈ $105.31K USD Cash + Short-term Investments

Total Assets

CA$1.34 Million

≈ $968.53K USD All company assets

Resilience Assessment

Moderate

Financial Resilience Level

Asset Resilience Ratio Trend (2017–2018)

This chart shows how Hemostemix Inc's Asset Resilience Ratio has changed over time. See Hemostemix Inc (HEM) net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Hemostemix Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Hemostemix Inc market cap and net worth.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	CA$0.00	0%
Short-term Investments	CA$145.58K	10.87%
Total Liquid Assets	CA$145.58K	10.87%

Asset Resilience Insights

Moderate Liquidity: Hemostemix Inc has 10.87% of assets in liquid form.
While adequate for normal operations, this level may limit flexibility during economic stress.
The company has significant short-term investments, indicating active treasury management.

Hemostemix Inc Industry Peers by Asset Resilience Ratio

Compare Hemostemix Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Biomarin Pharmaceutical Inc NASDAQ:BMRN	Biotechnology	3.28%
Summit Therapeutics PLC NASDAQ:SMMT	Biotechnology	0.00%
Argen-X F:1AE	Biotechnology	25.67%
Zhejiang Ausun Pharmaceutical Co Ltd SHG:603229	Biotechnology	0.21%
R&G PharmaStudies Co. Ltd. A SHE:301333	Biotechnology	35.96%
Shouyao Holdings (Beijing) Co. Ltd. A SHG:688197	Biotechnology	79.48%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	70.49%
Sunmax Biotechnology Co Ltd TWO:4728	Biotechnology	10.53%

Annual Asset Resilience Ratio for Hemostemix Inc (2017–2018)

The table below shows the annual Asset Resilience Ratio data for Hemostemix Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2018-12-31	0.00%	CA$0.00 ≈ $0.00	CA$1.66 Million ≈ $1.20 Million	--
2017-12-31	23.66%	CA$1.25 Million ≈ $907.60K	CA$5.30 Million ≈ $3.84 Million	--

pp = percentage points

About Hemostemix Inc

V:HEM Canada Biotechnology

Market Cap

$8.18 Million

CA$11.31 Million CAD

Market Cap Rank

#27339 Global

#1183 in Canada

Share Price

CA$0.06

Change (1 day)

+0.00%

52-Week Range

CA$0.06 - CA$0.15

All Time High

CA$13.40